Could be a pump and dump. The stock has to show numbers, meaningful PR, and Berlin needs to be talking to big pharma for a sale or a monetary partnership.This could be just a daytrader spike as the market is going crazy over low oil. ROSG needs a positive event!
What are the odds that TEVA acquires ROSG this year around the same time the Thyroid test becomes active? Professor Yitzhak Peterburg is now chairman of TEVA and a director 1 on ROSG board. He should know the value of ROSG and could bid at 200 million. TEVA did 20 billion last year and I would think that ROSG has patents/IP that would be a benefit to any big pharma. Thoughts?
More likely someone like BMS. If the new sequencing partnership can develop, a drug developer would benefit more than a manufacturer of mainly generics. For either, it would only be a drop in a bucket.
Jake -Lots of folks are looking for a buyout, but share price is still within a few percent of all time lows. I'd rather see ROSG license their patents and have prospects of a steady long-term revenue and profit stream. If the science really is good, you don't want to sell it when you're just starting to see some benefits. FB didn't sell out when they had a million users.
ROSG needs more proof of marketability (different from efficacy) before it will be of any value to anyone. It has been a long wait for some of us long-term holders. My fear now is that I die before ROSG. Peter
Most doctors have to want to admin the drug metabolizing test and most are so overwhelmed they don't want or have the ability to read or understand the results which needs to interpreted by the testing lab. That being said with the new Obama care regulations most if not all these swab test will and should be handled by a pharmacy which in turn will let doctors know when they write drug prescription if the patients can metabolize a drug.
tjr, I appreciate your input, but please try to rephrase your comment more concisely. The garbled constructions like "have to want" and "want or have" "will and should" make what I sense is an important point nearly incomprehensible. As the comment stands, I don't know if you are making a positive or a negative comment. Thanks.
Peter, I hope I die before ROSG does! True, we need more transparency about sales results, and I expect to hear more in the next conference call.
So we know that these type of test are valuable. Is Berlin going to realize that he cannot do this alone and needs to be looking for a buyer as this market is getting hotter!
Is it coincidence the that letter came the same day FMI was bought by Roche? This company might be making some money but it is not making a profit. They are going to run out of money and Berlin needs to start looking at selling or diluting again. This company should be sold and 250-300 million is a fair price. Right now most of us are underwater with this stock.